News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InViragen Enlists Advanced BioScience Laboratories, Inc. for Manufacture of Master Virus Seed Stock for Plague Vaccine Development



2/8/2012 7:24:05 AM

FORT COLLINS, Colo. & ROCKVILLE, Md.--(BUSINESS WIRE)--Inviragen, Inc. and Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies. Under this agreement, ABL will be responsible for the production and characterization of a master virus seed stock, a reservoir of virus produced under strict cGMP conditions, which will be used to support Inviragen’s development of a vaccine against plague. In addition, ABL will develop purified vaccine material to be used in future toxicology studies.

Read at BioSpace.com


comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES